Clinical trials: Adjuvant Radiotherapy
Squamous Cell Carcinoma of the Head and Neck
ERBITUX® Followed by Adjuvant Treatment With Chemoradiation and ERBITUX® for Locally Advanced Head and Neck Squamous Cell Carcinoma
There are currently no useful tests to identify patients who will respond to cetuximab therapy, notably because EGFR levels do not correlate with the clinical responses observed.
- Trial name
- NCT01218048
- Testing
- Cetuximab, Surgery, Post-surgical radiation
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Robert Ferris
Breast Neoplasms
The Impact of Chronic Mitochondrial Antioxidant Supplementation on CardiovascularToxicity in Breast Cancer Patients
Investigate the protective effect of chronic MitoQ supplementation on cardiovascular toxicity induced by doxorubicin-based adjuvant chemotherapy in breast cancer patients.
- Trial name
- NCT05146843
- Testing
- Mitoquinone
- Volunteers
- 44 people
- Sponsor
- D'Or Institute for Research and Education
Squamous Cell Carcinoma of Head and Neck
A Trial Evaluating the Addition of Nivolumab to Cisplatin-RT for Treatment of Cancers of the Head and Neck
The purpose of this study is to determine the efficacy of nivolumab + cisplatin-RT relative to standard of care (SOC) cisplatin-RT alone, using the disease-free survival (DFS by investigator imaging assessment) as primary…
- Trial name
- NIVOPOSTOP (NCT03576417)
- Testing
- Cisplatin, Nivolumab, RT
- Where
- France
- Volunteers
- 680 people
- Sponsor
- Groupe Oncologie Radiotherapie Tete et Cou
Upper Urinary Tract Urothelial Carcinoma
A Clinical Study of the Efficacy and Safety of Disitamab Vedotin in Combination With Radiotherapy for the Adjuvant Treatment of HER2 Overexpressing UTUC Patients With High Risk Factors for Recurrence After Radical Surgery
In this study, 60 patients with HER2 overexpression UTUC with high-risk recurrence factors after radical surgery were proposed to be enrolled, and were assigned to Cohort I (receiving adjuvant therapy group) and Cohort II…
- Trial name
- NCT06210490
- Testing
- Disitamab Vedotin, Radiotherapy, Standard of Care
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Peking University First Hospital
Chemoradiotherapy
Upfront Bevacizumab/témozolomide for Gliomastomas With Neurological Impairment
New approaches are needed for patients newly diagnosed with bulky glioblastoma (GB) and/or with severe neurological impairment that cannot benefit from first line temozolomide (TMZ)-basedn chemoradiotherapy.
- Trial name
- TEMOBEVA (NCT03623347)
- Testing
- TMZ and BEV induction before chemoradiotherapy
- Where
- France
- Volunteers
- 70 people
- Sponsor
- Centre Hospitalier Universitaire, Amiens
Brain and Central Nervous System Tumors
Everolimus, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma
RATIONALE: Everolimus may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking some of the blood flow to the tumor.
- Trial name
- NCT00553150
- Testing
- everolimus, temozolomide, radiation
- Where
- 178 sites in United States
- Volunteers
- 122 people
- Sponsor
- Alliance for Clinical Trials in Oncology
Ductal Carcinoma in Situ, Breast Cancer
Novel Cavity Marking Technique in Breast Cancer Patients Undergoing Breast Conservation Surgery With Oncoplastic Reconstruction for the Delivery of Adjuvant Radiotherapy and Accuracy of Recommended Re-excisions
This study will investigate a novel approach to marking surgical cavity margins following tumor resection, to allow for more accurate radiotherapy following oncoplastic surgery.
- Trial name
- NCT06903468
- Testing
- Novel cavity marking technique
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- University of Florida
Glioblastoma
Post Marketing Surveillance: Newly Diagnosed Glioblastoma Multiforme Treated With Radiotherapy/Temozolomide and Adjuvant Temozolomide (Study P04739)
The purpose of this surveillance is to collect more safety and efficacy data in "non-study" patients during concomitant and adjuvant temozolomide therapy.
- Trial name
- NCT00704808
- Testing
- Primary surgical treatment, Radiotherapy, Temozolomide
- Volunteers
- 180 people
- Sponsor
- Merck Sharp & Dohme LLC
Breast Cancer
A Prospective Phase II Study for Adjuvant Hypofractionated Intensity-modulated Proton Radiotherapy for Post Operative Breast Cancer With Implantation Reconstruction
The incidence of breast reconstruction failure after conventional photon radiotherapy for breast cancer is about 18.7%. At present, there is limited data on proton radiotherapy for post operative breast cancer with implantation…
- Trial name
- NCT05692674
- Testing
- adjuvant hypofractionated intensity-modulated proton radiotherapy
- Where
- China
- Volunteers
- 67 people
- Sponsor
- Shanghai Proton and Heavy Ion Center
Pancreatic Cancer
Combination Chemotherapy, and Radiation Therapy in Treating Patients With Locally Advanced Pancreatic Cancer
RATIONALE: Drugs used in chemotherapy work in different ways to stop tumor cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage tumor cells.
- Trial name
- NCT00089024
- Testing
- fluorouracil, gemcitabine hydrochloride, leucovorin calcium
- Where
- United States
- Volunteers
- 29 people
- Sponsor
- University of Nebraska
Ureter Cancer, Renal Pelvic Carcinoma
Postoperative Adjuvant Immunotherapy Combined with Radiotherapy Versus Surgery Alone in Locally Advanced UTUC
This is a prospective cohort study to analyse the safety and efficacy of postoperative adjuvant radiotherapy combined with immunotherapy versus surgery alone group of UTUC patients with T3-4 stages or lymph nodes metastasis(N+)…
- Conditions
- Ureter Cancer, Renal Pelvic Carcinoma, Advanced Urothelial Carcinoma
- Trial name
- NCT06598761
- Testing
- Immunotherapy+radiotherapy, surveillance alone
- Where
- 2 sites in China
- Volunteers
- 60 people
- Sponsor
- Peking University First Hospital
Oral Tongue Squamous Cell Carcinoma
A Study of Radiation Therapy After Surgery in People With Oral Tongue Squamous Cell Carcinoma
This study will test whether limiting standard photon intensity modulated radiation therapy (IMRT) to exclude the oral tongue surgical site can decrease the risk of side effects caused by oral radiation.
- Trial name
- NCT06485778
- Testing
- Photon intensity modulated radiation therapy (IMRT), Life questionnaire's
- Where
- 7 sites in United States
- Volunteers
- 24 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Prostate Cancer
Radiotherapy - Adjuvant Versus Early Salvage
Radical prostatectomy (RP) is the most common curative approach offered to men with newly diagnosed prostate cancer. Unfortunately, up to half of these patients will have factors placing them at high risk of their cancer…
- Trial name
- RAVES (NCT00860652)
- Testing
- Adjuvant Radiotherapy, Early Salvage Radiotherapy
- Where
- 36 sites in Australia, New Zealand
- Volunteers
- 333 people
- Sponsor
- Trans Tasman Radiation Oncology Group
Sarcoma, Hyperbaric Oxygen Therapy
Hyperbaric Oxygen Therapy for Soft Tissue Sarcoma Pilot Study
A parallel-group randomized pilot trial at a single institution (Duke University) on the effect of postoperative hyperbaric oxygen therapy on wound healing in patients with soft tissue sarcoma undergoing surgical resection with…
- Trial name
- NCT03144206
- Testing
- Hyperbaric oxygen
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Duke University
Cervical Carcinoma, Endometrial Carcinoma
Hypofractionated Radiotherapy for the Treatment of Cervical or Endometrial Cancer
This clinical trial studies the feasibility of using hypo-fractionated radiotherapy for the treatment of cervical or endometrial cancer.
- Trial name
- RT-PACE (NCT05139368)
- Testing
- Hypofractionated Radiation Therapy
- Where
- United States
- Volunteers
- 22 people
- Sponsor
- University of Utah
Radiotherapy, Adjuvant, Phyllodes Breast Tumor
Effects of Radiotherapy in Borderline and Malignant Phyllodes Tumors After R0 Resection
Breast phyllodes tumors (PT) are rare fibroepithelial neoplasms originating from stromal tissue and account for less than 1% of all breast tumors.
- Conditions
- Radiotherapy, Adjuvant, Phyllodes Breast Tumor, Prognosis
- Trial name
- NCT06780059
- Testing
- Adjuvant Radiotherapy, R0 resection
- Where
- 3 sites in China
- Volunteers
- 480 people
- Sponsor
- Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Breast Cancer
Ten Fraction Adjuvant Hypofractionated Radiotherapy in Node Positive Breast Cancer
Post-operative loco-regional (LR) hypofractionated radiotherapy (Hypo-RT) is an attractive approach in locally advanced breast cancer (LABC).
- Trial name
- HIPOMAMMLINF (NCT04792346)
- Testing
- breast/chest wall radiotherapy
- Where
- Italy
- Volunteers
- 61 people
- Sponsor
- Regina Elena Cancer Institute
Endometrial Cancer, Gastrointestinal Complications
Prospective Randomised Phase II Trial Evaluating Adjuvant Pelvic Radiotherapy Using Either IMRT or 3-Dimensional Planning for Endometrial Cancer. ICORG 09-06
Post-operative radiotherapy is internationally accepted as standard practice in the management of high-risk endometrial cancer1. Whilst it has no proven impact on overall survival it significantly increases local control.
- Conditions
- Endometrial Cancer, Gastrointestinal Complications, Radiation Toxicity, Urinary Complications
- Trial name
- NCT01164150
- Testing
- 45 Gy/25 fractions
- Where
- 5 sites in Ireland
- Volunteers
- 92 people
- Sponsor
- Cancer Trials Ireland
Prostatic Neoplasms
Adjuvant Radiation Therapy vs. Watchful Waiting Following Radical Prostatectomy in High Risk Prostate Cancer
The purpose of this study is to determine whether adjuvant radiotherapy following radical prostatectomy in prostate cancer patients with positive margins or capsular penetration improves biochemical, overall and/or cancer…
- Trial name
- NCT02668718
- Testing
- Adjuvant radiotherapy
- Volunteers
- 250 people
- Sponsor
- Helsinki University Central Hospital
Cervical Cancer
Randomized Control Trial on Efficacy and Safety of Concurrent and Adjuvant Chemotherapy for the Cervical Cancer
The standard treatment of local advanced cervical cancer is concurrent chemoradiotherapy. The 3 year disease free survival was about 50-70%.
- Trial name
- NCT02703961
- Testing
- concurrent chemotherapy with cisplatin, concurrent chemotherapy with docetaxel, pelvic radiotherapy
- Where
- 3 sites in China
- Volunteers
- 598 people
- Sponsor
- Air Force Military Medical University, China